PROGRAM WEDNESDAY 7 DECEMBER h Check in
|
|
- Chester Dennis
- 5 years ago
- Views:
Transcription
1 WEDNESDAY 7 DECEMBER 7.00 h Check in 8.00 h Opening Remarks by Raymond F. Schinazi 8.10 h Presentation of David Barry DART Achievement Award Raymond F. Schinazi, PhD, DSc - Emory University, USA 8.20 h David Barry DART Achievement Award Lecture: The Discovery of SIV and Development of Monkey Models for the Study of HIV/ AIDS Ronald C. Desrosiers, PhD - University of Miami, USA Session 1 Chair Cure Session (Sponsored by amfar) Rowena Johnston - amfar, USA Raymond F. Schinazi - Emory University, USA 8.50 h Controversies and Misconceptions in HIV Reservoir Research Mario Stevenson, PhD - University of Miami/GVN, USA 9.10 h HIV-1 Macrophage Reservoirs: Lessons from Host Macrophage Specific Restriction Factor, SAMHD1 Baek Kim, PhD - Emory University, USA 9.30 h Humanized Mice as Models in Drug Development for Antiviral Therapies J. Victor Garcia-Martinez, PhD - University of North Carolina, USA 9.50 h Sustained Virologic Control in SIV+ Macaques Siddappa Byrareddy, PhD - University of Nebraska Medical Center, USA h Panel Discussion h Differential responses of memory CD4+ T cell subsets to HIV latency reversing agents D. Kulpa, Emory University, USA h HIV-1 dynamics under integrase inhibitor therapy suggests a subset of cells with slow integration R.M. Ribeiro, Los Alamos National Laboratory, USA Non- O_01 O_ h Coffee break Session 2 New Drugs for HIV Baek Kim - Emory University, USA Ronald C. Desrosiers - University of Miami, USA h State of the Art Lecture Integrase Inhibitors Today and Tomorrow Jay Grobler, PhD - Merck Inc., USA Non-
2 11.35 h Development of a New Class of Allosteric Inhibitors of HIV-1 Integrase with Promising Activity Against Resistance Mutations Eddy Arnold, PhD - Rutgers University, USA h CryoEM Structures and Atomic Model of the HIV-1 Strand Transfer Complex Intasome Dmitry Lyumkis, PhD - Salk Institute, USA h Panel Discussion h Lunch break h Free afternoon Session 3 Inflammation and Cure Mario Stevenson - University of Miami, USA David Thomas - Johns Hopkins School of Medicine, USA h State of the Art Lecture Current Clinical Therapies for HIV Remission David Margolis, MD - University of North Carolina USA h Impact of Jak Inhibitors on HIV Reservoir Maintenance, Lifespan and Expansion in Primary T Cells and Macrophages Christina Gavegnano, PhD - Emory University, USA Non- Oral Abstract Presentation h Anti HIV drug candidate abx464 prevents intestinal inflammation by producing IL22 in activated macrophages J. Tazi, Laboratoire coopératif ABIVAX-CNRS-UM, France Non- O_ h Cure and Controversies Debate Baek Kim, PhD - Emory University, USA (Speaker) David Margolis, MD - University of North Carolina, USA (Speaker) Mario Stevenson, PhD - University of Miami, USA (Discussant) Charles Boucher, MD, PhD - Erasmus Medical Center, The Netherlands (Discussant) Rowena Johnston, PhD - amfar, USA (Discussant) Veronica Miller, PhD - Berkeley University, USA (Discussant) Non h Dinner
3 THURSDAY 8 DECEMBER Rowena Johnston - amfar, USA Charles Boucher - Erasmus Medical Center, The Netherlands 8.30 h Presentation of Gertrude Elion Distinguished Lecturer Award Rowena Johnston, PhD - amfar, USA 8.40 h Gertrude Elion Distinguished Lecturer Award Lecture Stories on Scientific Discoveries that Transformed HIV into a Manageable Disease Mark Wainberg,PhD - McGill University, Canada Session 4 New Drugs and NeuroAIDS Ladislau Kovari - Wayne State University, USA Charles Boucher - Erasmus Medical Center, Holland 9.10 h Management of Neurocognitive Impairment of Aging Populations Living with HIV Scott Letendre, MD - University of California, USA 9.30 h EFdA (4'-Ethynyl-2-fluoro-2'-deoxyadenosine) a Powerful Nucleoside Analog for HIV Infections Hiroaki Mitsuya, MD, PhD - National Cancer Institute, USA 9.50 h Panel Discussion Non- Non h Development of a protease inhibitor-based single-tablet complete HIV-1 regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (DCFTAF) B. Baugh, Janssen Research & Development LLC, USA h Antiviral Activity of tenofovir alafenamide against HIV-1 with thymidine analog mutation(s) and M184V C. Callebaut, Gilead, Clinical Virology, USA Non- O_04 O_ h Coffee break Session 5 Co-infections, Immunology and Public Health Raymond Schinazi - Emory University, USA Eddy Arnold - Rutgers University, USA h Collateral Damage with Antiviral Therapy David Thomas, MD, MPH - Johns Hopkins School of Medicine, USA h AAV Vector to Deliver Potent Broadly Neutralizing Antibody for Treatment Purpose Ronald C. Desrosiers, PhD - University of Miami, USA h HIV Knowledge and Hope in Africa Carol A. Harris, MD - Albert Einstein College of Medicine, USA Non-
4 12.00 h State of the Art Lecture Phylogenetics and Intervention Strategies Richard Harrigan, PhD - British Columbia Centre for Excellence in HIV, Canada Oral Abstract Presentation h Predicting Antiviral Drug Toxicity Using Contractility Analysis Of Human IPSC Derived Cardiomyocytes Brian D. Herman, Emory University School of Medicine, USA Non- O_ h Lunch break h Free afternoon FRIDAY 9 DECEMBER Session 6 Emerging Viruses I: Epidemiology, Pathogenesis & Treatment Hiroaki Mitsuya - National Institutes of Health, USA Mark Wainberg - McGill University, Canada 8.30 h State of the Art Lecture What Do We Really Know About Dengue Viruses Oscar Perng, PhD - National Cheng Kung University, Taiwan 9.00 h Insights into Viral Pathogenesis and Antiviral Strategies for Zika Alan Perelson, PhD - Los Alamos, USA 9.20 h Global Burden and Novel Treatment of Noroviruses Ladislau Kovari, PhD - Wayne State University, USA 9.40 h Zika Neuropathies Beyond Microcephaly Maurício Lacerda Nogueira, MD, PhD - Medicine School of São José do Rio Preto (FAMERP), Brazil Non h In Silico Approaches Towards Broadly Active Flavivirus Protease Inhibitors Bryan D. Cox, Emory University, USA h Jak 1/2 Inhibition Modulates Production of Replication Competent Zika Virus in Primary Human Hofbauer, Trophoblast and Neuroblastoma Cells Leda Bassit, Emory University, USA Non- O_06 O_ h Coffee break
5 Session 7 Emerging Viruses II: Diagnosis and Treatment Alan Perelson - Los Alamos, USA Oscar Perng - National Cheng Kung University, Taiwan h State of the Art Lecture Research efforts to combat ZIKA: The Miami experience David Watkins - University of Miami, USA h Zika-Specific Antibodies for Prophylaxis and Detection David Watkins - University of Miami, USA h Rapid Zika Detection for Resource-Limited Regions Mark Sharkey, PhD - Discidium/University of Miami, USA h Closing Remarks: Outlook Over the Horizon Raymond F. Schinazi, PhD, DSc - Emory University, USA Lunch on your own (vouchers provided for those who stay until the end)
ABSTRACTS. HIV DART & Emerging Viruses December 2016, Los Cabos, Mexico
HIV DART & Emerging Viruses 206 7-9 December 206, Los Cabos, Mexico Abstract #O_0 HIV Reservoirs, Persistence and Eradication Differential responses of memory CD4+ T cell subsets to HIV latency reversing
More informationTherapies For Viral Hepatitis By Raymond F. Schinazi
Therapies For Viral Hepatitis By Raymond F. Schinazi If looking for the ebook Therapies for Viral Hepatitis by Raymond F. Schinazi in pdf format, then you have come on to faithful site. We present the
More informationResearch Priorities to Inform Public Health and Medical Practice for Domestic Zika Virus: A Workshop
Research Priorities to Inform Public Health and Medical Practice for Domestic Zika Virus: A Workshop February 16, 2016 National Academy of Sciences - Auditorium 2101 Constitution Ave NW Washington, DC
More informationArboviruses: A Global Public Health Threat
Arboviruses: A Global Public Health Threat Les Pensières Center for Global Health Veyrier-du-Lac - France 20-22 June 2018 Steering Committee: Duane Gubler Mauricio Lacerda Nogueira Jacques Louis Christopher
More informationA Quarterly Update on HIV Prevention Research. Vol. 8 No. 2
What is it? What could it do? Key Facts Antibodies Passive immunization is the transfer of pre-made antibodies to a person. Passive immunization using today's pre-made antibodies can involve infusion delivered
More informationINTERNATIONAL CONFERENCE ON MYELOID CELLS AND HIV ITALY 1-3 SEPTEMBER 2018 MEETING PROSPECTUS.
INTERNATIONAL CONFERENCE ON MYELOID CELLS AND HIV ITALY 1-3 SEPTEMBER 2018 MEETING PROSPECTUS ADVANCING HEALTH GLOBALLY THROUGH INNOVATIVE PROGRAMS DESIGNED FOR THE HEALTHCARE PROFESSIONAL 2 TABLE OF CONTENTS
More informationCLINICAL PATHWAY TRACK AGENDA TUESDAY, AUGUST 23, 2016
CLINICAL PATHWAY TRACK AGENDA TUESDAY, AUGUST 23, 2016 MORNING PLENARY LECTURES: LIBERTY BALLROOM (M4) 9:00 9:15 AM Welcome and Introductions Conference Co-Chairs: Laura W. Cheever, MD, ScM; Michael S.
More informationAntiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutation(s) and M184V
Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutation(s) and M184V Christian Callebaut, PhD Gilead Sciences, Foster City, CA, USA HIV DART AND EMERGING VIRUSES 12/08/2016
More informationSecond China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security
Second China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security May 17-19 2017, Wuhan, China Meeting Program Note: Each report will take 25 minutes including
More information10 5 TH TH WORKSHOP INTERNATIONAL WORKSHOP ON CO-INFECTION NEW ANTIVIRALS IN CLINICAL PRACTICE HIV & HEPATITIS AMSTERDAM, PARIS, FRANCE THE NETHERLANDS 12-13 JUNE 2014 4-5 DECEMBER 2015 MEETING PROSPECTUS
More informationPREDICTING SUSCEPTIBILITY AND RESISTANCE FOR HEPATITIS B VIRUS CAPSID ASSEMBLY EFFECTORS
PREDICTING SUSCEPTIBILITY AND RESISTANCE FOR HEPATITIS B VIRUS CAPSID ASSEMBLY EFFECTORS BRYAN D. COX, PH.D. EMORY UNIVERSITY, DEPARTMENT OF PEDIATRICS LABORATORY OF BIOCHEMICAL PHARMACOLOGY EMORY CENTER
More informationWorking Group#1: Trial Endpoints, Biomarkers & Definitions
Working Group#1: Trial Endpoints, Biomarkers & Definitions Forum HIV Cure Project: Focus on The Regulatory Pathway June 17, 2014 www.hivforum.org Comments from co-chairs john mellors and mike miller www.hivforum.org
More informationAtul Humar, MD, MSc Director, Transplant Program, University Health Network, University of Toronto
TIME PROGRAM TITLE 7:30 8:15 Registration and Continental Breakfast 8:15 8:30 Welcoming Remarks TOPIC: VIRUSES Session Chair: Shahid Husain CMV: What is New, What s Hot Atul Humar, MD, MSc Director, Transplant
More informationPRELIMINARY RYAN WHITE HIV/AIDS PROGRAM CLINICAL CARE CONFERENCE AGENDA
PRELIMINARY RYAN WHITE HIV/AIDS PROGRAM CLINICAL CARE CONFERENCE AGENDA 9:00 9:15 AM Welcome and Introductions TUESDAY, DECEMBER 15, 2015 9:00 AM 5:05 PM 9:15 9:45 AM Update on the Ryan White HIV/AIDS
More informationProfessor of Medicine, Johns Hopkins Bloomberg School of Public Health; Director, Johns Hopkins Center for Global Health, Baltimore, MD
Sunday 25 th August: Registration and Opening Ceremony. Registration 11.00 am 5.00 pm Opening Ceremony 6.30 pm 10.00 pm Master of Ceremonies: Ismae Whyms 6:30 pm National Anthem of Ariba 6:35 pm Opening
More informationGLOBAL INVESTMENT IN HIV CURE RESEARCH AND DEVELOPMENT IN 2017 AFTER YEARS OF RAPID GROWTH FUNDING INCREASES SLOW
GLOBAL INVESTMENT IN HIV CURE RESEARCH AND DEVELOPMENT IN 2017 AFTER YEARS OF RAPID GROWTH FUNDING INCREASES SLOW TOWARDS AN CURE PEOPLE FOCUSED SCIENCE DRIVEN JULY 2018 A GLOBAL STRATEGIC APPROACH TOWARDS
More informationversus CD4. PoC - Messaging - Specificity and - Ethics sensitivity of HIV - Feedback from diagnostic tests demonstration projects
PRE-CONFERENCE WORKSHOPS WEDNESDAY, 24 OCTOBER 2018 10h00 14h00 Pre-Conference Workshop Pre-Conference Workshop Pre-Conference Workshop Pre-Conference Workshop ITREMA trial feedback PrEP for the private
More informationProgram. Wednesday, 30 May
Wednesday, 30 May 9:00 Opening of the meeting 9:15 The role of the human microbiome on HIV infection Roger Paredes, MD, PhD Irsi Caixa Foundation, Barcelona, Spain Session 1 The future of the HIV epidemic
More information"Development and Clinical Progress. of DNA Vaccines" Program
Paul-Ehrlich-Institut International Conference "Development and Clinical Progress of DNA Vaccines" Paul-Ehrlich-Institut, Langen, Germany October 6-8, 1999 Program CBER/FDA INTERNATIONAL ASSOCIATION FOR
More informationForward Looking Statements
Slide title Forward Looking Statements This presentation may contain forward looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited
More informationSubmitted by Timothy M. Block, Ph.D. President and Chief Scientific Advisor
Princeton, NJ Submitted by Timothy M. Block, Ph.D. President and Chief Scientific Advisor For the past eight years, the has invited a small group of the world s hepatitis thought leaders from academia,
More informationAANP. American Association of Neuropathologists. 93 rd Annual Meeting. June 8-11 Orange County, California. Meeting at a Glance
AANP American Association of Neuropathologists 2017 93 rd Annual Meeting June 8-11 Orange County, California Meeting at a Glance 2017 SPECIAL COURSE Genetics, Genomics, and Epigenomics in Clinical Neuropathology
More informationProgram Agenda. Ottawa Heart Research Conference (OHRC): Steadying the Future of Atrial Fibrillation. Thursday, June 2 nd (Day 1)
Ottawa Heart Research Conference (OHRC): Steadying the Future of Atrial Fibrillation Thursday, June 2 nd (Day 1) 8:00 am Welcome Message Drs. David Birnie, Peter Liu, and Thierry Mesana 8:15 9:35 am Session
More informationNewsletter. August 7, Visit
Share: Tweet Newsletter August 7, 2013 Jump to a Topic: Upcoming Events Funding Opportunities Conferences and Meetings Announcements Check out our new website! We are excited to announce the launching
More informationSession 1B - Auditorium Adult cases - Adherence - Mental health - STIs - Opportunistic Infections - TB - Drug Interactions Panel discussion
CONFERENCE PROGRAMME WEDNESDAY, 24 OCTOBER 2018 08h00 18h00 Registration OFFICIAL MEETING COMMENCES 14h00 15h30 Session 1A Adolescent cases - Teen pregnancy and breast feeding - Previously on PrEP, now
More informationAn Evolutionary Story about HIV
An Evolutionary Story about HIV Charles Goodnight University of Vermont Based on Freeman and Herron Evolutionary Analysis The Aids Epidemic HIV has infected 60 million people. 1/3 have died so far Worst
More informationPROGRAM RNA VIRUS PERSISTENCE MEETING: MECHANISMS AND CONSEQUENCES. AUGUST 23-25, 2018 Institute of Virology, Medical Center - University of Freiburg
PROGRAM RNA VIRUS PERSISTENCE MEETING: MECHANISMS AND CONSEQUENCES AUGUST 23-25, 2018 Institute of Virology, Medical Center - University of Freiburg WELCOME Mechanisms and consequences of RNA virus persistent
More informationNew Treatments to Reduce Liver Damage From Hepatitis B
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/gi-insights/new-treatments-to-reduce-liver-damage-from-hepatitisb/3994/
More informationThe Third D: Long Term Solutions to End the Epidemic. Mitchell Warren Executive Director, AVAC 12 February 2014
The Third D: Long Term Solutions to End the Epidemic Mitchell Warren Executive Director, AVAC 12 February 2014 Key clinical trial milestones: HIV vaccine research First HIV vaccine trial opens Phase
More informationCompartmentalized HIV and SIV Populations in the Central Nervous System Are Associated with Neuropathogenesis
Compartmentalized HIV and SIV Populations in the Central Nervous System Are Associated with Neuropathogenesis Gretja Schnell Graduate Student Laboratory of Ronald Swanstrom Department of Microbiology and
More informationMEETING PROSPECTUS. HIV CLINICAL FORUM INTEGRASE INHIBITORS DURBAN, SOUTH AFRICA 16 July 2016
MEETING PROSPECTUS HIV CLINICAL FORUM INTEGRASE INHIBITORS DURBAN, SOUTH AFRICA 16 July 2016 VIROLOGY EDUCATION BILTSTRAAT 106 3572 BJ UTRECHT THE NETHERLANDS +31 30 230 7140 INFO@VIROLOGY-EDUCATION.COM
More informationRe-envisioning Our Field: Advancing Racial Equity and Leading Innovation in Capacity Building 2018 Alliance Conference
Re-envisioning Our Field: Advancing Racial Equity and Leading Innovation in Capacity Building 2018 Alliance Conference Hartford, CT October 10-12, 2018 January 30, 2018: Dear Colleagues, We are writing
More informationPMC ATM and ATR activities maintain replication fork integrity during SV40 chromatin replication. PLoS Pathog. 2013;9(4):e PMC
Class Date Instructors Topic Papers Scott Hensley and Jianxin You Vaccine Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. Cell. 2016 Jul 28;166(3):609 23. doi:10.1016/j.cell.2016.06.043.
More informationWESTERN REGIONAL ALCOHOLICS ANONYMOUS SERVICE ASSEMBLY. Our Big Book 80 Years, 71 Languages
WESTERN REGIONAL ALCOHOLICS ANONYMOUS SERVICE ASSEMBLY Our Big Book 80 Years, 71 Languages February 22 nd - 24 th 2019 The Coast Capri Hotel 1171 Harvey Avenue, V1Y 6E8, Kelowna B.C. (250) 860-6060 Friday,
More informationOctober 15 & WORKSHOP ON DRUG DISCOVERY AND INFECTIOUS DISEASE. IMéRA, Maison des astronomes, Marseille
October 15 & 16 2015 WORKSHOP ON DRUG DISCOVERY AND INFECTIOUS DISEASE IMéRA, Maison des astronomes, Marseille Organizing committee Philippe HALFON Hôpital Européen, laboratoire Alphabio, service maladies
More informationEACS HIV Summer School PRELIMINARY PROGRAMME
EACS HIV Summer School Thursday, August 30, 2018 Monday, September 3, 2018 Montpellier, France This 5-day residential course is designed for clinicians experienced in HIV management who want an update
More informationTowards a block and lock strategy: LEDGINs hamper the establishment of a reactivation competent HIV reservoir.
Abstract no. MOLBPEA13 Towards a block and lock strategy: LEDGINs hamper the establishment of a reactivation competent HIV reservoir. G. Vansant,,A. Bruggemans, L. Vranckx, S. Saleh, I. Zurnic, F. Christ,
More informationJuly 5 & 6, 2018, Paris SCIENTIFIC PROGRAM
www.paris-nash.org Dear Colleagues, We are delighted to announce the 4th Paris NASH Meeting to be held on July 5-6 th 2018. This international academic meeting is aimed to do a deep-dive into many aspects
More informationAre Immune Modulators Really Needed to Cure HBV infection?
Are Immune Modulators Really Needed to Cure HBV infection? Harry L.A. Janssen Francis Family Chair of Hepatology Director Toronto Centre for Liver Disease University Health Network University of Toronto,
More informationApproaching a Cure Daniel R. Kuritzkes, MD
Approaching a Cure Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker is a consultant and/or has received speaking honoraria
More informationcure research HIV & AIDS
Glossary of terms HIV & AIDS cure research Antiretroviral Therapy (ART) ART involves the use of several (usually a cocktail of three or more) antiretroviral drugs to halt HIV replication. ART drugs may
More informationLYON. FRANCE NOVEMBER / 2013 TRANSLATIONAL RESEARCH IN CHRONIC VIRAL HEPATITIS - BRIDGING BASIC SCIENCE AND CLINICAL RESEARCH
LYON. FRANCE NOVEMBER 29-30 / 2013 TRANSLATIONAL RESEARCH IN CHRONIC VIRAL HEPATITIS - BRIDGING BASIC SCIENCE https://events.easl.eu/eventportal/ Information/MLYON2013/HOME.aspx Abstract submission deadline:
More informationEXPLORING THE IMPACT OF SEX DISCREPANCIES IN HIV TREATMENT AND CURE
EXPLORING THE IMPACT OF SEX DISCREPANCIES IN HIV TREATMENT AND CURE CECILE DELILLE LAHIRI, M.D, M.SC ASSISTANT PROFESSOR DIVISION OF INFECTIOUS DISEASES MAY 18, 2016 OUTLINE Describe discrepancy between
More informationthe Office of Research Application Portal: Materials to submit:
Title: PAR 17 237: Centers for AIDS Research (P30) Slots: 1 Internal Deadline: LOI: External Deadline: Award Information: Submission Process: May 26, 2018, 5pm PDT 30 days prior to the application due
More informationThe Intersection of Technology, HAART Adherence, and Drug Abuse Treatment Washington Marriott Wardman Park Washington, DC. Agenda
The Intersection of Technology, HAART Adherence, and Drug Abuse Treatment Washington Marriott Wardman Park Washington, DC Thursday, March 4, 8:00 a.m. 5:00 p.m. Friday, March 5, 8:00 a.m. 1:00 p.m. Agenda
More informationOral Versus Injectable Delivery, Impact on Adherence/Tolerability
Oral Versus Injectable Delivery, Impact on Adherence/Tolerability 2 nd European HIV Forum Ian McGowan MD DPhil FRCP University of Pittsburgh, PA, USA Glasgow, 22 nd October, 2016 Overview Why do we need
More informationSCIENTIFIC and SOCIAL PROGRAM
4th European Days of Albinism, 7-11 March 2018 Hurdal Vision and Activity Center, Oslo, Norway Organized by Albinism Europe and NFFA SCIENTIFIC and SOCIAL PROGRAM Wednesday, 7 March 2018-17:00 SHUTTLE
More informationAntivirals. Lecture 20 Biology 3310/4310 Virology Spring 2017
Antivirals Lecture 20 Biology 3310/4310 Virology Spring 2017 You can t go back and you can t stand still. If the thunder don t get you, then the lightning will. JERRY GARCIA The Wheel (lyrics by Robert
More informationHIV cure: current status and implications for the future
HIV cure: current status and implications for the future Carolyn Williamson, PhD Head of Medical Virology, Faculty Health Sciences, University of Cape Town CAPRISA Research Associate, Centre of Excellence
More informationIII. What are the requirements for taking and passing this course?
1 Molecular Virology Lecture # 1: Course Introduction I. Instructor and Background Dr. Richard Kuhn rjkuhn@bragg.bio.purdue.edu B-129 Lilly Hall 494-1164 Office Hours - Wednesday 10:30-11:30 II. Objective:
More informationLong-Acting Antiretrovirals for HIV
Long-Acting Antiretrovirals for HIV R.M. Gulick, MD, MPH Rochelle Belfer Professor in Medicine Chief, Division of Infectious Diseases Weill Cornell Medicine New York City Disclosures None Single Tablet
More informationIn vivo analysis of HIV replication and persistence in the myeloid compartment
In vivo analysis of HIV replication and persistence in the myeloid compartment J. Honeycutt, A. Wahl, J. Foster, R.A. Spagnulo and J. Victor Garcia Division of Infections Diseases UNC Center for AIDS Research
More informationWe have one of the World s Most Advanced Functional HIV Cures under development
Source : labiotech.eu, 04/07/2016 We have one of the World s Most Advanced Functional HIV Cures under development Abivax has recently announced that it s likely that its most advanced program in hepatitis
More informationSCIENTIFIC and SOCIAL PROGRAM
4th European Days of Albinism, 7-11 March 2018 Hurdal Vision and Activity Center, Oslo, Norway Organized by Albinism Europe and NFFA SCIENTIFIC and SOCIAL PROGRAM Wednesday, 7 March 2018 Airport shuttle
More informationMatias Jaureguiberry-Bravo: Exploring a Novel Approach to Preventing HIV-Associated Brain Disorders
Matias Jaureguiberry-Bravo: Exploring a Novel Approach to Preventing HIV-Associated Brain Disorders Since the advent of antiretroviral drugs in the late1990s, the medical community has made great progress
More information13th Residential Course on Clinical Pharmacology of Antiretrovirals. Turin, January 2018
13th Residential Course on Clinical Pharmacology of Antiretrovirals Turin, 17-19 January 2018 NOTES 13th Residential Course on Clinical Pharmacology of Antiretrovirals Turin, 17-19 January 2018 COURSE
More informationModule R: Recording the HIV Reservoir
Module R: Recording the HIV Reservoir Satish K. Pillai, Ph.D. MODULE LEADER Satish Pillai amfar Institute for HIV Cure Research Module R Team Michael Busch Timothy Henrich Sheila Keating Sulggi Lee Henry
More informationCROI 2016 Review: Immunology and Vaccines
Frontier AIDS Education and Training Center CROI 2016 Review: Immunology and Vaccines Meena Ramchandani MD MPH Acting Instructor, University of Washington March 2016 This presentation is intended for educational
More informationThe HIV life cycle. integration. virus production. entry. transcription. reverse transcription. nuclear import
The HIV life cycle entry reverse transcription transcription integration virus production nuclear import Hazuda 2012 Integration Insertion of the viral DNA into host chromosomal DNA, essential step in
More informationCommittee on Medication Assisted-Treatment for Opioid Use Disorder. October 29, Time Task/Objective Leader/Moderator
Health and Medicine Division Board on Health Sciences Policy Committee on Medication Assisted-Treatment for Opioid Use Disorder October 29, 2018 Time Task/Objective Leader/Moderator OPEN SESSION 1:00pm
More informationDr Jintanat Ananworanich
BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Dr Jintanat Ananworanich US Military HIV Research Program in Bethesda Maryland, USA 9-10 October 2014, Queen Elizabeth II Conference Centre,
More informationDEPARTMENT OF VIROLOGY
DEPARTMENT OF VIROLOGY National Health Laboratory Services, KZN, Inkosi Albert Luthuli Central Hospital Nelson R Mandela School of Medicine, University of Kwa-Zulu Natal Introduction to the Virology of
More informationInves)gación básica y curación del VIH- 1
Inves)gación básica y curación del VIH- 1 Javier Mar)nez- Picado (jmpicado@irsicaixa.es) 23 rd Conference on Retroviruses and Opportunis5c Infec5ons February 22-25, 2016 Boston, Massachuse8s UNIVERSITAT
More informationXVII International Symposium on Respiratory Viral Infections March 2015 Vancouver, Canada
March 2015 As of January 3, 2015 Chairs: W. Abdullah Brooks Centre for Vaccine Sciences (ICDDR, B), Johns Hopkins Bloomburg School of Public Health, Dhaka, Bangladesh and Baltimore, Maryland, Arnold Monto
More informationHIV 101: Fundamentals of HIV Infection
HIV 101: Fundamentals of HIV Infection David H. Spach, MD Professor of Medicine University of Washington Seattle, Washington Learning Objectives After attending this presentation, learners will be able
More information2018 PITTSBURGH INTERNATIONAL LUNG CONFERENCE Pulmonary Medicine: Basic Biology and Novel Therapies
2018 PITTSBURGH INTERNATIONAL LUNG CONFERENCE Pulmonary Medicine: Basic Biology and Novel Therapies PROGRAM AGENDA Thursday, October 4, 2018 7:00 8:00 am Registration, Refreshments, and Poster Viewing
More informationDIOXIN SYMPOSIUM MEETING PLANNING
DIOXIN SYMPOSIUM MEETING PLANNING History & General Information A listing of future and past Dioxin Symposia can be found on the Symposium page. The International Dioxin Symposium has been held annually
More informationRound table discussion Patients with multiresistant virus : A limited number, but a remarkable deal Introduction
Disclosure statement: Dr. Santoro reports personal fees from ViiV Healthcare, Gilead and JANSSEN Cilag Round table discussion Patients with multiresistant virus : A limited number, but a remarkable deal
More informationCLINICAL PEARLS OF NEW HIV MEDICATIONS PHARMACIST OBJECTIVES TECHNICIAN OBJECTIVES. At the end of this presentation pharmacists will be able to:
CLINICAL PEARLS OF NEW HIV MEDICATIONS Cindy Lou Zoellner, PharmD, BCPS Added Qualifications in Infectious Diseases Senior Clinical Pharmacy Specialist in HIV Parkland Health & Hospital System Volunteer
More informationADVANCES IN SKELETAL MUSCLE BIOLOGY IN HEALTH AND DISEASE CONFERENCE PROGRAM
ADVANCES IN SKELETAL MUSCLE BIOLOGY IN HEALTH AND DISEASE CONFERENCE PROGRAM WEDNESDAY, March 6, 2019 Reitz Union, University of Florida 12:15-1:15pm Grant-Writing Workshop, Ground Floor Room G330 12:15-12:45
More informationFrom Mosquitos to Humans: Genetic evolution of Zika Virus
Article: From Mosquitos to Humans: Genetic evolution of Zika Virus Renata Pellegrino, PhD Director, Sequencing lab Center for Applied Genomics The Children s Hospital of Philadelphia Journal Club Clinical
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationInternational Symposium on the Ehlers-Danlos Syndromes
It is with great pleasure that we invite you to participate in the International Symposium on the Ehlers-Danlos Syndromes September 26 29, 2018 The conference will take place in beautiful Ghent, Belgium,
More informationDay1- Monday 7 May 2018 OPENING REMARKS AND COURSE INTRODUCTION EPIDEMIOLOGY AND ECOLOGY VIROLOGY
Day1- Monday 7 May 2018 OPENING REMARKS AND COURSE INTRODUCTION 08.30 09.00 Hassan Zaraket (Faculty of Medicine, American University of Beirut, Lebanon) & John Wood (National Institute for Biological Standards
More informationALOPECIA AREATA RESEARCH SUMMIT Forging the Future
ALOPECIA AREATA RESEARCH SUMMIT Forging the Future PRELIMINARY PROGRAM Tuesday, December 4 Wednesday, December 5, 2018 Lerner Hall, Columbia University, New York City, USA Summit Co-Chairs Jerry Shapiro,
More information9:30 11:00 Redefining Treatment Expectations in Moderate-to-Severe Psoriasis Room: Macdonald ABCD, Fairmont Chateau Whistler Resort
Thursday, October 26, 2006 9:30 11:00 Redefining Treatment Expectations in Moderate-to-Severe Psoriasis Session Objectives: Dermatologists participating in this symposium will: Discuss practical management
More informationEarly Antiretroviral Therapy
Early Antiretroviral Therapy HIV Cure Research Training Curriculum HIV and Cure Early ART Presented by: Jintanat Ananworanich, MD, PhD June 2016 The HIV CURE research training curriculum is a collaborative
More informationDEPARTMENT OF VIROLOGY
DEPARTMENT OF VIROLOGY NELSON R MANDELA SCHOOL OF MEDICINE, UNIVERSITY OF KWAZULU-NATAL, and INKOSI ALBERT LUTHULI CENTRAL HOSPITAL, KZN BRANCH, NATIONAL HEALTH LABORATORY SERVICE Biomedscience III Virology
More informationEarly Intervention and Diagnosis in Paediatric Neurodevelopment Defects in Brazil, November, Rio de Janeiro, Brazil
Early Intervention and Diagnosis in Paediatric Neurodevelopment Defects in Brazil, 29-30 November, Rio de Janeiro, Brazil Introduction The trend in childhood disability has shifted over recent decades
More informationIt takes more than just a single target
It takes more than just a single target As the challenges you face evolve... HIV mutates No HIV-1 mutation can be considered to be neutral 1 Growing evidence indicates all HIV subtypes may be prone to
More informationThe Discovery of SIV and Development of Monkey Models for the Study of HIV/AIDS. Ronald C Desrosiers University of Miami Miller School of Medicine
The Discovery of SIV and Development of Monkey Models for the Study of HIV/AIDS Ronald C Desrosiers University of Miami Miller School of Medicine 10 FEBRUARY 1984 Infectious Diseases Branch, National
More informationScottish Medicines Consortium
Scottish Medicines Consortium raltegravir, 400mg film-coated tablet (Isentress) No. (461/08) Merck, Sharp and Dohme Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment
More informationPediatric HIV Cure Research
Pediatric HIV Cure Research HIV Cure Research Training Curriculum Pediatric HIV Cure Research Presented by: Priyanka Uprety,MSPH, PhD Laboratory of Deborah Persaud, MD Johns Hopkins University July 2016
More informationA VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART
BIOE 301 LECTURE 10 MITALI BANERJEE A VACCINE FOR HIV HIV HAART Visit wikipedia.org and learn the mechanism of action of the five classes of antiretroviral drugs. (1) Reverse transcriptase inhibitors (RTIs)
More informationDr Marta Boffito Chelsea and Westminster Hospital, London
Dr Marta Boffito Chelsea and Westminster Hospital, London Speaker Name Statement Dr Marta Boffito has received travel and research grants from and has been an advisor for Janssen, Roche, Pfizer, ViiV,
More informationBEAT-HIV Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy
BEAT-HIV Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy We are pleased to announce that the National Institutes of Health (NIH) has awarded nearly $23 million to co-principal
More informationBACTERIAL, VIRAL AND INFECTIOUS DISEASES
15+ Interactive Sessions 10+ Keynote Lectures 40+ Scientific Sessions 3+ Workshops 30+ Posters B2B Meetings BACTERIAL DISEASES 2018 Annual Conference on BACTERIAL, VIRAL AND INFECTIOUS DISEASES August
More informationThe potential role of PD-1/PD-L1 blockade in HIV Remission and Cure Strategies
The potential role of PD-1/PD-L1 blockade in HIV Remission and Cure Strategies Stephen Mason Director, Discovery Virology Bristol-Myers Squibb Community Cure Workshop 2015 Sunday, Feb 22, 2015 Seattle,
More informationBLT mice in HIV prophylaxis
BLT mice in HIV prophylaxis Martina Kovarova, Ph.D. Assistant Professor UNC at Chapel Hill September 18, 2017 BLT mice Bone Marrow-Liver-Thymus Melkus, et al., Nature (2006) BLT humanized mice preparation
More informationDestruction of the Residual Active HIV-1 Reservoir by Env-specific Immunotoxin
Destruction of the Residual Active HIV-1 Reservoir by Env-specific Immunotoxin J. Victor Garcia-Martinez, Ph.D. University of North Carolina, at Chapel Hill IAS 2013 Towards an HIV Cure Symposium Delivering
More informationPreventive and therapeutic HIV vaccines. Markus Bickel Infektiologikum Frankfurt
Preventive and therapeutic HIV vaccines Markus Bickel Infektiologikum Frankfurt No conflicts to declare Disclosures Background FAQ: by patients and colleagues Publication about promising results, especially
More informationClinical and Epidemiological aspects of Zika: What we know and what we don t know
Clinical and Epidemiological aspects of Zika: What we know and what we don t know Maurício Lacerda Nogueira, MD, PhD Associate Professor Department of Microbiology and Infectious Diseases Faculdade de
More informationHepatitis B Foundation 6 th Annual Princeton Workshop November 10 11, 2000 Doylestown, PA
6 th Annual Princeton Workshop November 10 11, 2000 Doylestown, PA Submitted by Timothy M. Block, Ph.D. President and Chief Scientific Advisor The 6th annual Princeton HBV Workshop was unique, even by
More informationEstablishment and Targeting of the Viral Reservoir in Rhesus Monkeys
Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys Dan H. Barouch, M.D., Ph.D. Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center Ragon Institute of MGH, MIT,
More informationPhase II clinical trial TEmAA. Didier Koumavi EKOUEVI, MD PhD (Principal Investigator)
The combination of Tenofovir-Emtricitabine (Truvada ): a new antiretroviral (ARV) regimen for the prevention of mother-to-child transmission of HIV-1 (PMTCT) in resource-limited settings Phase II clinical
More informationImmunodeficiency. (2 of 2)
Immunodeficiency (2 of 2) Acquired (secondary) immunodeficiencies More common Many causes such as therapy, cancer, sarcoidosis, malnutrition, infection & renal disease The most common of which is therapy-related
More informationThe 3 rd Nagasaki Symposium on Tropical and Emerging Infectious Diseases and The 9 th Nagasaki-Singapore Medical Symposium.
The Global Center-of-Excellence Program -Global Control Strategy of Tropical and Emerging Infectious Diseases- The 3 rd Nagasaki Symposium on Tropical and Emerging Infectious Diseases and The 9 th Nagasaki-Singapore
More informationThe preferential selection of K65R in HIV-1 subtype C is attenuated by nucleotide polymorphisms at thymidine analogue mutation sites
Journal of Antimicrobial Chemotherapy Advance Access published June 7, 2013 J Antimicrob Chemother doi:10.1093/jac/dkt204 The preferential selection of K65R in HIV-1 subtype C is attenuated by nucleotide
More informationDistribution and Effectiveness of Antiretrovirals in the Central Nervous System
Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Scott Letendre, MD Associate Professor of Medicine HIV Neurobehavioral Research Center and Antiviral Research Center University
More informationTRANS-NIH PLAN FOR HIV RELATED RESEARCH
National Institutes of Health FY 2018 TRANS-NIH PLAN FOR HIV RELATED RESEARCH Prepared by the Office of AIDS Research Maureen M. Goodenow, Ph.D. NIH Associate Director for AIDS Research and Director, Office
More information